Advertisement
U.S. markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.0300-0.0200 (-0.66%)
At close: 04:00PM EDT
3.1000 +0.07 (+2.31%)
After hours: 06:01PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.0500
Open3.0800
Bid3.0100 x 700
Ask3.0600 x 200
Day's Range3.0100 - 3.1850
52 Week Range2.7600 - 12.3600
Volume413,252
Avg. Volume809,109
Market Cap678.49M
Beta (5Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-1.5900
Earnings DateApr 23, 2024 - Apr 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CVAC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CureVac N.V.
    Analyst Report: CureVac N.V.CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more